四環醫藥(00460.HK):醫用皮膚護理凝膠及醫用皮膚修復凝膠兩款產品獲批
格隆匯1月10日丨四環醫藥(00460.HK)宣佈,集團旗下渼顏空間生物科技(吉林)有限公司所研發的醫用皮膚護理凝膠及醫用皮膚修復凝膠獲得中華人民共和國國家藥品監督管理局頒發的醫療器械註冊證。
醫用皮膚護理凝膠及醫用皮膚修復凝膠可用於光電或者水光等醫美治療後的皮膚護理或修復。醫用皮膚護理凝膠可在創口表面形成保護層,起到物理屏障作用,在醫美治療後即刻使用可減少創口感染和發炎的機率,並能促進創口的快速癒合;醫用皮膚修復凝膠可用於過敏性皮膚,在醫美治療後皮膚狀態一般在短期內(7天左右)較敏感,可以使用該凝膠減少過敏症狀,儘快使皮膚恢復最佳狀態。
根據弗若斯特沙利文報吿,中國醫療器械類敷料產品的市場規模由2016年的人民幣約2.3億元增長至2020年的人民幣約41.8億元,年均複合增長率約為105.7%。預計到2025年醫療器械類敷料產品的市場規模將達到人民幣約201.4億元,2020年至2025年年複合增速預計為約37%。
公司表示,此次醫用皮膚護理凝膠及醫用皮膚修復凝膠兩款產品獲批,不僅標誌着集團醫美產品自研管線的進一步落地,而且豐富和擴大了集團醫美平台的產品組合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.